---
title: "Fennec Pharma | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 15.11 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286465194.md"
datetime: "2026-05-14T20:38:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286465194.md)
  - [en](https://longbridge.com/en/news/286465194.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286465194.md)
---

# Fennec Pharma | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 15.11 M

Revenue: As of FY2026 Q1, the actual value is USD 15.11 M, beating the estimate of USD 13.84 M.

EPS: As of FY2026 Q1, the actual value is USD 0.01.

EBIT: As of FY2026 Q1, the actual value is USD -451 K.

Fennec Pharmaceuticals Inc. operates as a single operating and reportable segment focused on the commercialization of PEDMARK®/PEDMARQSI®.

#### Segment Revenue

-   PEDMARK product sales, net: $15,108 thousand for the three months ended March 31, 2026, compared to $8,751 thousand for the same period in 2025.

#### Operational Metrics

-   Cost of product sales: $570 thousand for the three months ended March 31, 2026, compared to $373 thousand for the same period in 2025.
-   Research and development expenses: $49 thousand for the three months ended March 31, 2026, decreased by $45 thousand from $94 thousand for the same period in 2025.
-   Selling and marketing expenses: $11,422 thousand for the three months ended March 31, 2026, increased by $8,195 thousand from $3,227 thousand for the same period in 2025.
-   General and administrative expenses: $3,186 thousand for the three months ended March 31, 2026, decreased by $2,679 thousand from $5,865 thousand for the same period in 2025.
-   Total operating expense: $15,227 thousand for the three months ended March 31, 2026, compared to $9,559 thousand for the same period in 2025.
-   Loss from operations: -$119 thousand for the three months ended March 31, 2026, an improvement from -$808 thousand for the same period in 2025.
-   Net income/(loss): $201 thousand for the three months ended March 31, 2026, compared to -$1,165 thousand for the same period in 2025.
-   Interest expense: -$7 thousand for the three months ended March 31, 2026, decreased by $585 thousand from -$592 thousand for the same period in 2025.
-   Interest income: $339 thousand for the three months ended March 31, 2026, increased by $103 thousand from $236 thousand for the same period in 2025.

#### Cash Flow

-   Net cash provided by operating activities: $2,379 thousand for the three months ended March 31, 2026, compared to net cash used in operating activities of -$4,318 thousand for the same period in 2025.
-   Net cash provided by investing activities: $0 thousand for both the three months ended March 31, 2026, and 2025.
-   Net cash provided by financing activities: $1,012 thousand for the three months ended March 31, 2026, compared to $359 thousand for the same period in 2025.
-   Net cash flow: $3,391 thousand increase for the three months ended March 31, 2026, compared to a -$3,959 thousand decrease for the same period in 2025.

#### Unique Metrics

-   Cash and cash equivalents: $40,179 thousand as of March 31, 2026, compared to $36,788 thousand as of December 31, 2025.
-   Other current assets: $26,701 thousand as of March 31, 2026, compared to $30,255 thousand as of December 31, 2025.
-   Current liabilities: $9,586 thousand as of March 31, 2026, compared to $10,518 thousand as of December 31, 2025.
-   Working capital: $57,294 thousand as of March 31, 2026, compared to $56,525 thousand as of December 31, 2025.
-   Accumulated deficit: -$229,221 thousand as of March 31, 2026, compared to -$229,422 thousand as of December 31, 2025.
-   Total stockholders’ equity: $37,675 thousand as of March 31, 2026, compared to $35,472 thousand as of December 31, 2025.
-   Outstanding Shares: As of March 31, 2026, there were 34,541 thousand common shares, 111 thousand warrants, 512 thousand RSU and PSU Awards, and 7,229 thousand stock options outstanding.

#### Future Outlook and Strategy

Fennec Pharmaceuticals Inc. aims to establish PEDMARK® as the standard of care for cisplatin-induced ototoxicity prevention by increasing awareness and expanding adoption, supported by an expanded sales team and strategic partnerships. The company’s partner, Norgine, is expanding PEDMARQSI® launches in international markets, while Fennec Pharmaceuticals Inc. evaluates opportunities in Japan and supports further studies to characterize PEDMARK®’s use. Fennec Pharmaceuticals Inc. believes existing cash and expected revenues will fund operations for at least the next twelve months, and it continues to pursue strategic alternatives for capital management.

### Related Stocks

- [FENC.US](https://longbridge.com/en/quote/FENC.US.md)

## Related News & Research

- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [ERG announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/294572882.md)
- [ARES CAPITAL CORPORATION ANNOUNCES JUNE 30, 2026 FINANCIAL RESULTS AND DECLARES THIRD QUARTER 2026 DIVIDEND OF $0.48 PER SHARE | ARCC Stock News](https://longbridge.com/en/news/294187076.md)
- [Vale updates financial events calendar for 2026](https://longbridge.com/en/news/294418484.md)
- [Equatorial Energia updates financial calendar for 2026 disclosures](https://longbridge.com/en/news/294368263.md)